Neulasta

Latest stories

13h
FOX Business
3 Biotechs With Potential Big-Time Upsideout in the next 12 months. Coherus' stock has been on the rise since reporting
3 Biotechs With Potential Big-Time Upside
FOX Business / Posted 13 hours ago
out in the next 12 months. Coherus' stock has been on the rise since reporting positive data for its biosimilar for Amgen's Neulasta in July. Coherus submitted a biologics license application (BLA)for its Neulasta copycat in August. Since Amgen's... Read more
13h
FOX Business
3 Biotechs With Potential Big-Time Upsideout in the next 12 months. Coherus' stock has been on the rise since reporting
3 Biotechs With Potential Big-Time Upside
FOX Business / Posted 13 hours ago
out in the next 12 months. Coherus' stock has been on the rise since reporting positive data for its biosimilar for Amgen's Neulasta in July. Coherus submitted a biologics license application (BLA)for its Neulasta copycat in August. Since Amgen's... Read more
26d
Fortune
Novartis Just Got Some Great News In Its Battle for Amgen's Market Sharebiologics. In July, the company revealed that the FDA had rejected its biosimil
Novartis Just Got Some Great News In Its Battle for Amgen's Market Share
Fortune / Posted 26 days ago
biologics. In July, the company revealed that the FDA had rejected its biosimilar of a different Amgen product called Neulasta. For its part, Amgen is working on its own biosimilars, including for the top-selling drug in the world: AbbVie’s... Read more
8 related stories
26d
Swissinfo
Novartis Taps Biosimilar Experience in Europe to Snag U.S. SalesSandoz plans to roll out five major biosimilars by the end of the decade, inclu
Novartis Taps Biosimilar Experience in Europe to Snag U.S. Sales
Swissinfo / Posted 26 days ago
Sandoz plans to roll out five major biosimilars by the end of the decade, including versions of Enbrel and Neulasta, AbbVie Inc.’s Humira and Roche Holding AG’s Rituxan -- biologics that generated about $44 billion in 2015 sales... Read more
8 related stories

People in this news